Incruse Ellipta is intended as a once-daily maintenance treatment to be administered via GSK’s Ellipta inhaler.
GSK plans to begin distributing the drug in the fourth quarter of this year.
More Articles on FDA Approvals:
FDA Grants Accelerated Approval to Lung Cancer Treatment Drug
FDA Approves DNA Test for Primary Cervical Cancer Screening
FDA Approves First Drug to Treat Castleman’s Disease
